29/06/2007
In conformity with the Transparency Directive’s chapter 5 (DTR 5.6.1), the Board of ReGen Therapeutics Plc (the ‘Company’) announces the following:
As at the date of this announcement, the Company’s issued share capital consists of 1,025,887,710 Ordinary Shares with a nominal value of 0.1 pence each, with voting rights (‘Ordinary Shares’).
The Company does not hold any Ordinary Shares in Treasury.
Therefore the total number of Ordinary Shares in the Company with voting rights is 1,025,887,710.
The above figure of 1,025,887,710 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.
For further information please contact:
Percy Lomax
ReGen Therapeutics
Tel. 020 7153 4920
Andrew Marshall
Greycoat Communications
Tel. 020 7960 6007
Andrew Baker / Cecil Jordaan / Rory Creedon
HB Corporate
Tel. 020 7510 8561